Arbutus Biopharma Corporation (NASDAQ:ABUS) headquartered in Burnaby, will host a conference call for the investment community to discuss the 3Q20 financial results on 5th November 2020 at 8:45 AM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.arbutusbio.com
Earnings Expectation
Arbutus Biopharma Corporation is reporting third quarter financial results on Thursday 5th November 2020, before market open.
According to analysts surveyed by Thomson Reuters, ABUS is expected to report 3Q20 loss of $ 0.22 per share from revenue of $ 1.66 million. For the full year, analysts anticipate top line of $ 6.65 million, while looking forward to loss of $ 0.92 per share bottom line.
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. Its HBV product pipeline consists of AB-506, a capsid inhibitor that has shown improved potency and pharmacokinetics over its first generation capsid inhibitor; and AB-423, which is in pre-clinical studies. The company also develops RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach to treating disease.
